A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Phase 1 Recruiting
453 enrolled
KAT6
Phase 2 Recruiting
320 enrolled
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Phase 2 Recruiting
110 enrolled
LIMITLESS
Phase 3 Recruiting
30 enrolled
DeLLphi-312
Phase 3 Recruiting
330 enrolled
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Phase 2/3 Recruiting
596 enrolled
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Phase 3 Recruiting
480 enrolled
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
76 enrolled
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Phase 2 Recruiting
170 enrolled
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Phase 1 Recruiting
45 enrolled
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Phase 1/2 Recruiting
398 enrolled
DeLLphi-306
Phase 3 Recruiting
400 enrolled
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Phase 1 Recruiting
399 enrolled
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Phase 1 Recruiting
350 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
Phase 1 Recruiting
240 enrolled
DELTA-101
Phase 1 Recruiting
396 enrolled
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Phase 2/3 Recruiting
1,260 enrolled
ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer
Phase 3 Recruiting
460 enrolled
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Phase 1/2 Recruiting
594 enrolled
CheckMate-1533
Phase 2 Recruiting
76 enrolled
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Phase 1 Recruiting
364 enrolled
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Phase 3 Recruiting
750 enrolled
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Phase 1/2 Recruiting
150 enrolled
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Phase 3 Recruiting
698 enrolled
LuCa-MERIT-1
Phase 1 Recruiting
320 enrolled
THIO Sequenced With Cemiplimab in Advanced NSCLC
Phase 2 Recruiting
227 enrolled
PRESERVE-003
Phase 3 Recruiting
630 enrolled
FIT-001
Phase 1 Recruiting
300 enrolled
INTerpath-009
Phase 3 Recruiting
680 enrolled
CONVERGE
Phase 2 Recruiting
130 enrolled
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Phase 3 Recruiting
180 enrolled
SEZanne
Phase 2 Recruiting
180 enrolled
A Study of ZW251 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
100 enrolled
A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC
Phase 3 Recruiting
576 enrolled
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
Phase 1/2 Recruiting
160 enrolled
DL03
Phase 1 Recruiting
304 enrolled
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
949 enrolled
KEYNOTE-B98
Phase 1/2 Recruiting
110 enrolled
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Phase 1 Recruiting
694 enrolled
PALOMA-2
Phase 2 Recruiting
520 enrolled
INTerpath-002
Phase 3 Recruiting
868 enrolled
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
Phase 1 Recruiting
126 enrolled
COCOON
Phase 2 Recruiting
300 enrolled
TroFuse-007
Phase 3 Recruiting
614 enrolled
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Phase 1 Recruiting
383 enrolled
TroFuse-019
Phase 3 Recruiting
780 enrolled
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Phase 1 Recruiting
500 enrolled
KANDLELIT-004
Phase 3 Recruiting
600 enrolled
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/2 Recruiting
126 enrolled
eVOLVE-01
Phase 2 Recruiting
180 enrolled